Your browser doesn't support javascript.
loading
Advances of Lefamulin: a new pleuromutilin antibiotic / 药学学报
Acta Pharmaceutica Sinica ; (12): 1006-1015, 2021.
Article en Zh | WPRIM | ID: wpr-886979
Biblioteca responsable: WPRO
ABSTRACT
Lefamulin (BC-3781) is a semi-synthetic pleuromutilin antibiotic, approved for the treatment of community-acquired bacterial pneumonia (CABP) by Food and Drug Administration (USA) in August 2019, with the commodity name of Xenleta. It is the first pleuromutilin antibiotics used for systemic treatment of bacterial infections in human. Lefamulin binds to the peptidyl transferase center of the 50S ribosomal subunit to prevent peptide transfer, thus inhibits protein synthesis. Lefamulin displays expanded activity against gram-positive organisms, and also shows high activity against atypical microorganism like Mycoplasma pneumoniae. This review discusses the mechanism, bacterial spectrum of activity, preclinical and clinical data of Lefamulin.
Palabras clave
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Acta Pharmaceutica Sinica Año: 2021 Tipo del documento: Article
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Acta Pharmaceutica Sinica Año: 2021 Tipo del documento: Article